Bicara Therapeutics (BCAX) Income from Continuing Operations (2023 - 2026)
Bicara Therapeutics (BCAX) reported Income from Continuing Operations of 56211000.0 for Q1 2026, down 52.56% on a YoY basis from 118480093.02 in Q1 2025, and down 50.35% quarter-over-quarter from 37386000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Bicara Therapeutics has reported Income from Continuing Operations for 4 years, with the latest figure at 56211000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 52.56% year-over-year to 56211000.0; the trailing twelve-month figure through Mar 2026 stood at 157315000.0 (down 70.38% YoY), and the FY2025 full-year result was 137950000.0, down 102.88% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 56211000.0, down from 37386000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 12440000.0 in Q4 2023, with the low at 56211000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27040090.91 across 4 years, with a median of 22845000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations increased 23.48% — and 2025, when it sank 194.58%.
- Bicara Therapeutics' Income from Continuing Operations stood at 12440000.0 in 2023, then sank by 68.46% to 20957000.0 in 2024, then plunged by 78.39% to 37386000.0 in 2025, then slumped by 50.35% to 56211000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 56211000.0 (Q1 2026), 37386000.0 (Q4 2025), and 36330000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Bicara Therapeutics | 1.41 Bn | 1.41 Bn | - | -56.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | -37.39 Mn |
| Sep 30, 2025 | -36.33 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -36.85 Mn |
| Dec 31, 2024 | -20.96 Mn |
| Sep 30, 2024 | -17.48 Mn |
| Jun 30, 2024 | -17.05 Mn |
| Mar 31, 2024 | -12.51 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | -22.85 Mn |